colorectal cancer
Conditions
Interventions
Experimental group:Apatinib 250mg po, qd, continuous taken
XELOX: Oxaliplatin 135 mg/m2 Ivgtt d1, Capecitabine 1000mg/m2 d1-14, q3w
Control group:Bevacizumab 7.5mg/kg, q3w
Sponsors
Tangshan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histology diagnosed patients with recurrence and metastasis colorectal cancer or can not accept surgical treatment. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 3. Aged 18 to 75 years (man or female). 4. Life expectancy greater than or equal to 3 months. 5.Patients with asymptomatic brain metastases. 6.At least one measurable lesion (measuring=10mm on spiral CT scan, satisfying the criteria in RECIST1.1). 7.No chemotherapy contraindications. 8.Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Previous use of anti-angiogenic therapy. 2. Patients at high risk of bleeding. 3. Allergic to apatinib,bevacizumab,capecitabine and oxaliplatin. 4. Pregnant or lactating, or those with fertility and positive baseline pregnancy test, or those of childbearing age who are unwilling to take effective contraceptive measures throughout the trial. 5. The researchers think inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progress-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate (DCR);Overall survival (OS);Objective response rate (ORR);Safty; | — |
Countries
China
Contacts
Public ContactSun Guogui
Tangshan People's Hospital
Outcome results
None listed